Haleon plc Form 6-K Summary
Business context and reporting period
Haleon plc filed a Form 6-K for September 2026, dated 24 September 2026. The filing reports director/PDMR shareholding transactions under the UK Market Abuse Regulation. Haleon is a consumer health company focused on oral health, vitamins, minerals and supplements, pain relief, respiratory health, digestive health, and therapeutic skin health.
Financial metrics and liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, balance-sheet data, or other operating financial metrics.
Material changes versus the prior comparable period
No comparative-period financial information or business performance changes are disclosed. The material disclosure is the acquisition of Haleon ordinary shares through dividend reinvestment by two PDMRs on 22 September 2026.
| PDMR | Instrument | Transaction | Price | Volume | Venue |
|---|---|---|---|---|---|
| Dawn Allen, Chief Financial Officer | Ordinary shares, ISIN GB00BMX86B70 | Dividend reinvestment | £3.44631 | 2,317.19703 | London Stock Exchange |
| Brian McNamara, Chief Financial Officer | Ordinary shares, ISIN GB00BMX86B70 | Dividend reinvestment | £3.44631 | 12,208.83196 | London Stock Exchange |
| Brian McNamara, Chief Financial Officer | Ordinary shares, ISIN US4055521003 | Dividend reinvestment | $9.3801 | 2,139.05113 | London Stock Exchange |
Guidance, outlook, risks, and unusual items
The filing contains no management guidance, outlook, risk update, contingencies, or unusual operating items. The disclosed transactions were acquisitions resulting from dividend reinvestment and were identified as initial notifications.
Key facts for investors to verify
- Confirm the transaction date of 22 September 2026 and the filing date of 24 September 2026.
- Verify the share classes and identification codes: GB00BMX86B70 and US4055521003.
- Verify the reported prices, volumes, and London Stock Exchange venue for each transaction.
- Note that the filing provides no new financial performance or liquidity information.
- Confirm the reported PDMR roles and names in the company’s official regulatory disclosures.